ACXP Earnings

ACXP reported its earnings on 2026-05-12, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.59 by 0%. The stock experienced a -5.96% price change on the earnings day and a -11.93% change over the next five days, reflecting market reactions to the results.

Following ACXP's earnings announcement on 2026-05-12, the stock price moved by -5.96% on the day of the release. Over the subsequent five days, it saw a -11.93% change. Historically, ACXP's stock price tends to shift by an average of 12.44% in the 10 days leading up to earnings and -0.37% in the 10 days following, providing insight into potential market.

For , analysts estimate ACXP's annual revenue to reach undefined, while the EPS is projected at -1.50. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ACXP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ACXP's stock price typically moves by 12.44% in the 10 days before its earnings and -0.37% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.50 and revenue of undefined.

The earnings call highlights significant progress in clinical trials, a favorable FDA one-trial requirement, and an extended patent, all potentially reducing time to market and enhancing IP protection. Financials show reduced losses and prudent expense management. The Q&A reinforces confidence in trial strategies and FDA alignment. Although macroeconomic challenges exist, the overall sentiment is positive, suggesting a potential stock price increase in the short term, especially if the market recognizes the strategic advancements and financial discipline.